Robert W. Duggan - Dec 6, 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Director, 10%+ Owner
Signature: /s/ Ken Stratton
Stock symbol: PLSE
Transactions as of: Dec 6, 2023
Transactions value $: $809,387
Form type: 4
Date filed: 12/8/2023, 07:38 PM
Previous filing: Dec 7, 2023
Next filing: Dec 11, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLSE	Common Stock	Options Exercise	$59.1K	+9.93K	+0.03%	$5.95	36.6M	Dec 6, 2023	Direct
transaction	PLSE	Common Stock	Purchase	$750K	+82.8K	+0.23%	$9.06	36.7M	Dec 6, 2023	Direct	F1
holding	PLSE	Common Stock						352K	Dec 6, 2023	See footnote	F2
holding	PLSE	Common Stock						492K	Dec 6, 2023	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Options Exercise	$0	-9.93K	-100%	$0.00^*	0	Dec 6, 2023	Common Stock	9.93K	$5.95	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Volume-weighted average price.
F2	Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder.
F3	Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
F4	Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a quarterly basis following the Company's 2023 Annual Stockholder Meeting.